Twice-yearly Depemokimab (Depe) Reduces Exacerbations and Improves Quality of Life (QoL) in Patients (Pts) With Uncontrolled Asthma Symptoms at Baseline (BL): Subgroup Analyses of the Phase III SWIFT-1/2 Studies